Intellia's CrispR gene therapy trial for HAE is not a risk to BCRX | BCRX Message Board Posts


BioCryst Pharmaceuticals Inc.

  BCRX website

BCRX   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  12748 of 12775  at  6/28/2021 3:55:59 PM  by

kokopelli


 In response to msg 12746 by  moshes
view thread
Buy

Re: Intellia's CrispR gene therapy trial for HAE is not a risk to BCRX

 The drop in price is not likely due to Intellia's news.  Rather, more likely due to KalVista's news about the Phase II results for their oral treatment for HAE which looks like a direct competitor to Orladeyo


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 0  
   Views: 0 [2]
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
12750 Re: Intellia's CrispR gene therapy trial for HAE is not a risk to BCRX moegrabbedmythumb 1 7/1/2021 4:49:09 PM


Financial Market Data provided by
.
Loading...